3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Melanoma
34
Neoplasms
21
Carcinoma, Non-Small-Cell Lung
7
Brain Neoplasms
5
Skin Neoplasms
4
Neoplasm Metastasis
4
Glioma
4
Thyroid Carcinoma, Anaplastic
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Oligodendroglioma
2
Neurofibroma, Plexiform
2
Neurocytoma
2
Neuroblastoma
2
Lung Neoplasms
2
Histiocytosis, Langerhans-Cell
2
Glioblastoma
2
Ganglioneuroma
2
Ganglioglioma
2
Colorectal Neoplasms
2
Astrocytoma
2
Small Cell Lung Carcinoma
1
Recurrence
1
Rectal Neoplasms
1
Nonseminomatous germ cell tumor
1
Neurofibromatosis 1
1
Multiple Myeloma
1
Melanoma, Cutaneous Malignant
1
Leukemia, Hairy Cell
1
Gastrointestinal Stromal Tumors
1
Fever
1
Interventions
pegfilgrastim
3
Vancomycin
2
trametinib
1
dabrafenib
1
ceftobiprole medocaril
1
Teicoplanin
1
Mannose-Binding Lectin
1
Itraconazole
1
Granulocyte Colony-Stimulating Factor
1
Filgrastim
1
Doxorubicin
1
Docetaxel
1
Cyclophosphamide
1
Cefepime
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Fever
×
dabrafenib
×
Clear all
NCT03551626
2025-04-29
COMBI-APlus
Novartis
Phase 3
Completed
552 enrolled
12 charts